TPO and autoimmune thrombocytopenic purpura: Study patient 4 demonstrates the challenges with regional access to ITP therapies as she lost funding to her TPO-RA and was transitioned to fostamatinib with a platelet count of 193 × 109/L and was able to maintain a complete response (platelets > 100 × 109/L).